Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation
Authors:
Top Cited Papers
- 27 January 2026
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 335 (4) , 317-325
Abstract
Importance: Conventional wisdom holds that caffeinated coffee is proarrhythmic. Coffee is the most commonly consumed caffeinated beverage in the US, and a randomized trial assessing caffeinated coffee consumption in patients with atrial fibrillation (AF) has not previously been performed. Objective: To determine the effect of caffeinated coffee consumption compared with abstinence from coffee and caffeine on recurrent AF. Design, Setting, and Participants: This was a prospective, open-label, randomized clinical trial enrolling 200 current or previous (within past 5 years) coffee-drinking adults with persistent AF, or atrial flutter with a history of AF, planned for electrical cardioversion from 5 hospitals in the US, Canada, and Australia between November 2021 and December 2024. The date of final follow-up was June 5, 2025. Intervention: Patients were randomized in a 1:1 ratio to regular caffeinated coffee consumption vs coffee and caffeine abstinence for 6 months. Patients in the coffee consumption group were encouraged to drink at least 1 cup of caffeinated coffee daily. Patients in the abstinence group were encouraged to completely abstain from both caffeinated and decaffeinated coffee and other caffeine-containing products. Main Outcomes and Measures: The primary end point was clinically detected recurrence of AF or atrial flutter over 6 months. Results: Two hundred patients (mean [SD] age, 69 [11] years; 71% male) were randomized to caffeinated coffee consumption (n = 100) or coffee abstinence (n = 100). Baseline coffee intake was 7 cups (IQR, 7-18) per week in both groups. During follow-up, coffee intake in the consumption and abstinence groups was 7 (IQR, 6-11) and 0 (IQR, 0-2) cups per week, respectively, resulting in a between-group difference of 7 cups (95% CI, 7-7) per week. In the primary analysis, AF or atrial flutter recurrence was less in the coffee consumption (47%) than the coffee abstinence (64%) group, resulting in a 39% lower hazard of recurrence (hazard ratio, 0.61 [95% CI, 0.42-0.89]; P = .01). A comparable benefit of coffee consumption was observed with AF recurrence only. There was no significant difference in adverse events. Conclusions and Relevance: In this clinical trial of coffee drinkers after successful cardioversion, allocation to consumption of caffeinated coffee averaging 1 cup a day was associated with less recurrence of AF or atrial flutter compared with abstinence from coffee and caffeinated products. Trial Registration: ClinicalTrials.gov Identifier: NCT05121519Keywords
This publication has 46 references indexed in Scilit:
- Coffee Consumption, Additive Use, and Risk of Type 2 Diabetes—Results from 3 Large Prospective United States Cohort StudiesThe American Journal of Clinical Nutrition, 2025
- Association Between Coffee Consumption and Incident Atrial Fibrillation (from the Multi-Ethnic Study of Atherosclerosis [MESA])The American Journal of Cardiology, 2022
- Individualized Studies of Triggers of Paroxysmal Atrial FibrillationJAMA Cardiology, 2021
- Coffee Consumption and Incident TachyarrhythmiasJAMA Internal Medicine, 2021
- The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: a comprehensive review of the literatureEuropean Journal of Nutrition, 2017
- Caffeine Intake and Atrial Fibrillation Incidence: Dose Response Meta-analysis of Prospective Cohort StudiesCanadian Journal of Cardiology, 2014
- Alcohol and Vagal Tone as Triggers for Paroxysmal Atrial FibrillationThe American Journal of Cardiology, 2012
- Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul StudyAmerican Heart Journal, 2008
- Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillationThe American Journal of Cardiology, 2004
- Prevention of atrial fibrillation after cardioversion: results of the PAFAC trialEuropean Heart Journal, 2004